Clinical trial · Observational
Analysis of Clinical Characteristics and Study of Diagnostic Markers in Patients with Polycystic Ovary Syndrome
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators collected clinical data and serum samples of patients with polycystic ovary syndrome in this study, used statistical software such as SPSS for data analysis, and used experimental techniques such as ELISA to detect serum samples, aiming to explore the relationship between the body anthropometry, glucose and lipid metabolism, gonadal hormones and body fat distribution in patients with polycystic ovary syndrome and to discovery new biomarkers and promote the realization of more accurate personalized medicine.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Polycystic Ovary Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| This study does not involve any interventions | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- PCOS
- description
- 1. Oligomenorrhea/amenorrhea 2. Clinical androgen excess or biochemical androgen excess 3. Polycystic ovary showed by gynecological ultrasound
- interventionNames
- Other: This study does not involve any interventions
- label
- NOPCOS
- description
- not meet Rotterdam standards
- interventionNames
- Other: This study does not involve any interventions
Primary outcomes (1)
- measure
- diagnostic markers of PCOS patients
- timeFrame
- baseline
- description
- Fibrinogen-like-protein 1 (FGL1), is a novel hepatokine that plays an important role in hepatic steatosis, insulin resistance and obesity. There is no maximum or minimum value for this parameter and the higher scores mean a worse outcome.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Female aged 18- 45; * Meet Rotterdam criteria; Exclusion Criteria: * Women who are pregnant or have a pregnancy plan within six months; * Congenital adrenocortical hyperplasia; * Hyperprolactinemia; * Hyperthyroidism or hypothyroidism; * Abnormal liver function (≥ 3 times of the upper limit of normal range); * Abnormal renal function (GFR\<60ml/min/1.73m2); * Adrenal or ovarian tumors secreting androgens; * Used contraceptives, metformin, GLP-1RA, pioglitazone and contraceptives in the last 3 month.
References
Publications (1)
- DERIVEDSu K, Zhao Y, Chai H, Cai M, Dilimulati D, Zhang Y, Shao X, Qu S, Liu C, Zhang M. Remission of polycystic ovary syndrome based on the recovery of ovarian morphology identified by three-dimensional ultrasonography: a retrospective study. Front Endocrinol (Lausanne). 2026 Jul 30;17:1877873. doi: 10.3389/fendo.2026.1877873. eCollection 2026. PMID 42597837